Flupentixol
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
- Flupentixol
- Flupentixol: From Schizophrenia to Retinal Dystrophy with or without Extraocular Anomalies
Flupentixol: From Schizophrenia to Retinal Dystrophy with or without Extraocular Anomalies
One-Sentence Summary
Flupentixol is a thioxanthene antipsychotic originally used to treat schizophrenia. The TxGNN model predicts it may be effective for retinal dystrophy with or without extraocular anomalies, but there are currently 0 clinical trials and 0 publications supporting this prediction, so it rests on a computational prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia |
| Predicted New Indication | Retinal dystrophy with or without extraocular anomalies |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| New Zealand Market Status | Cancelled only (no currently valid authorization) |
| Number of Authorizations | 3 (all cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this report. Based on known pharmacology, flupentixol is a thioxanthene antipsychotic that binds dopamine receptors (D1, D2, D3 and D5). Its efficacy in schizophrenia is established, and it is also described as being used for depression.
No plausible mechanistic link to inherited retinal degeneration is supported by the data compiled for this report. The very high TxGNN score (0.9999) comes from a graph-based prediction alone. Retinal dystrophies are typically driven by genetic defects in photoreceptor or retinal pigment epithelium function, and nothing here suggests that dopamine receptor antagonism would address them. The prediction should therefore be regarded as a hypothesis-generating signal and not as evidence of benefit.
Other high-scoring predictions for this drug show the same pattern. They include Charcot-Marie-Tooth disease type 1G, congenital disorder of glycosylation with defective fucosylation, perisylvian polymicrogyria, hydranencephaly, several forms of myopia and atypical glycine encephalopathy. All are at evidence level L5, with no trials or literature. The myopia forms have only a speculative, indirect link through retinal dopamine in eye growth, and the direction of effect for an antagonist is unclear.
New Zealand Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 437301 | Fluanxol | Inj 20 mg per ml, 2 ml | Not available (cancelled) |
| 437298 | Fluanxol | Inj 20 mg per ml, 1 ml | Not available (cancelled) |
| 437271 | Fluanxol | Inj 100 mg per ml, 1 ml | Not available (cancelled) |
All three authorizations are for injectable products and all have been cancelled, so no valid single-ingredient or combination product is currently registered.
Safety Considerations
Package insert warnings and contraindications were not available for this report, and no contraindications were found in the knowledge graph. Please refer to the package insert for safety information.
Pharmacological interactions (receptor targets): The data lists flupentixol's binding to the human dopamine D1, D2, D3 and D5 receptors. These are pharmacological targets, not drug-drug interaction severity ratings, and no graded interaction levels were provided.
Other observation: In drug repurposing screens, flupentixol showed anti-SARS-CoV-2 activity. This is attributed to its cationic amphiphilic nature and a possible induction of phospholipidosis, which is a preclinical signal and not a clinical benefit.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a very high model score but no clinical trials, no publications and no plausible mechanistic link to retinal dystrophy. The drug also has no currently valid New Zealand authorization.
To proceed, the following is needed:
- Mechanism of action data (MOA) from DrugBank, to allow a proper mechanistic analysis
- Package insert warnings and contraindications from Medsafe, which are required before any safety screening
- Preclinical or mechanistic evidence linking dopamine receptor antagonism to the retinal dystrophy phenotype
- A review of the cancelled New Zealand authorizations, and of the available routes of administration, if development is considered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.